Not yet recruitingNAINTERVENTIONAL

Impact of a Cardiac Rehabilitation Program on Patients With Cardiac Amyloidosis

This study is investigating whether a specially designed exercise programme, known as cardiac rehabilitation, can help people living with cardiac amyloidosis. This condition can make it hard to exercise and can affect a person's quality of life. The main aim is to see if the programme improves how well the heart and lungs work during exercise, and if it's safe and practical for people with this condition. Researchers will also look at other aspects of exercise, how the heart functions, and general well-being. Everyone in the study will do the programme and have tests before it starts and again about three months later to see what changes have occurred.

At a glance

Status

Not yet recruiting

Phase

Sponsor

University Hospital, Montpellier

Enrolment target

Start

30 Apr 2026

Estimated completion

30 Jan 2029

Amyloidosis

What is this study about?

Heart amyloidosis is a condition where unusual proteins build up in the heart, making it stiff and harder for it to pump blood properly. This can make it very difficult to exercise, cause uncomfortable symptoms, and generally lower a person's quality of life. More and more people, especially older adults, are being diagnosed with this condition.

While we know cardiac rehabilitation (a special exercise and education programme) can help many people with heart problems, we don't fully understand its benefits for those with cardiac amyloidosis. Previous studies have been small or looked at very different groups of people. This new study aims to fill that gap by carefully checking the effects of a structured programme in people with heart amyloidosis.

The main goal is to find out if this rehabilitation programme can improve how well people with heart amyloidosis can exercise and if it makes them feel better in their day-to-day lives. Researchers will be looking at specific measures of heart and lung fitness during exercise, how the heart is working, and how participants feel overall.

Key takeaways

This study explores how a special exercise programme helps people with cardiac amyloidosis.
It aims to see if exercise ability and quality of life improve.
Participants will follow a 5-week supervised exercise programme.
Health checks will be done before and after the programme.
The study helps us understand the role of exercise in managing this heart condition.

Who may be eligible?

To join this study, you need to be an adult aged 18 or older with a specific type of heart amyloidosis, called transthyretin cardiac amyloidosis. You must also be able to do an exercise test.

There are some reasons why you might not be able to join. For instance, if you have very serious uncontrolled heart rhythm problems, severe heart failure (NYHA Class IV), or if you are pregnant or breastfeeding, the study might not be suitable for you. Also, you need to be able to understand what the study involves and agree to take part.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

Are you 18 years old or older?
Do you have a diagnosis of transthyretin cardiac amyloidosis?
Are you able to perform a standard exercise test?
Can you commit to a 5-week rehabilitation programme?

Answer every question to see your result.

What does participation involve?

If you take part in this study, you will go through a special cardiac rehabilitation programme for five weeks. This programme involves supervised exercise sessions (both aerobic, like cycling, and strength training) delivered by a team of experts, usually five days a week with two sessions each day.

Before the programme starts, you will have several health checks. These include an exercise test to see how well your heart and lungs work, a test to check your heart's function using electrical signals, a questionnaire about your quality of life, a blood test, and a blood pressure check while standing up. You will have all these tests again about three months after the rehabilitation programme finishes to see if there have been any changes. You'll need to be available to complete the rehabilitation programme within about a month of your initial exercise test.

Potential risks and benefits

Participating in this study may offer potential benefits, such as improved exercise ability and a better quality of life through the structured rehabilitation programme. While the programme is supervised, there's always a small risk of discomfort or rare complications with exercise, especially with a heart condition. All procedures will be carefully monitored. You have the right to withdraw from the study at any time without giving a reason, and this will not affect your usual medical care.

Locations (1)

KRIEF
Verified postcode
Montpellier, France

Common questions

What is cardiac rehabilitation?

It's a supervised programme of exercise and education designed to help people with heart conditions improve their health and well-being.

What is cardiac amyloidosis?

It's a heart condition where unusual protein deposits build up in the heart, making it stiff and affecting how it works.

Will I have to take any new medicines?

This study focuses on an exercise programme, not new medicines. Your existing medications will be continued as usual.

How long does the study last?

The rehabilitation programme is for 5 weeks, and you'll have tests before it starts and again about 3 months later.

Will I be in an experiment or a control group?

There is no separate control group in this study. Everyone who takes part will complete the rehabilitation programme, and researchers will compare your results before and after.

How to find out more

Susan Martinez, PhD

s-martinezjahnke@chu-montpellier.fr 04 67 33 52 56 Official trial record

Always speak to your GP or specialist before deciding to take part in a study.